Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.4
3.9
Journals
JCM
Special Issues
Clinical Management of Psoriatic Arthritis: Future Perspectives
share announcement

Clinical Management of Psoriatic Arthritis: Future Perspectives

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Immunology".

Deadline for manuscript submissions: 31 August 2024 | Viewed by 3657

Special Issue Editors

Dr. Alen Zabotti

E-Mail Website
Guest Editor
Rheumatology Clinic, Department of Medical Area, Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy
Interests: psoriatic arthritis; psoriasis; rheumatoid arthritis; ultrasonography
Special Issues, Collections and Topics in MDPI journals
Dr. Ivan Giovannini

E-Mail Website
Guest Editor
Rheumatology Clinic, Department of Medical Area, Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy
Interests: sjogren’s syndrome; psoriatic arthritis; ultrasonography; rheumatoid arthritis; gout; ostheoarthritis
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Psoriatic arthritis (PsA) is a chronic and inflammatory arthropathy, which in addition to skin and nail involvement may be associated with peripheral and axial joint involvement, enthesitis, dactylitis, and important comorbidities. At present, significant delays are reported in diagnosis for the majority of patients, impacting on long-term joint damage and functional disability. Registry data have shown the destructive and progressive nature of the disease; thus, early detection may prevent the loss of function and impairment in quality of life.

New imaging techniques may allow the early detection of PsA, and new therapeutic options have changed its clinical management in recent years. Therefore, early diagnosis and early treatment are two cornerstones to reach clinical remission and to stop articular damage.

Good practice in integrated rheumatological–dermatological clinical evaluation could be crucial for the early referral of psoriatic patients with articular symptoms, for tailored therapies that could work for both skin and joints, and for highlighting minimal psoriasis in early seronegative arthritis. Additionally, new diagnostic and therapeutic options are emerging, widening the medication spectrum available both for psoriasis and PsA.

In this Special Issue, we welcome the submission of original research and review articles presenting and discussing the screening tools and ultrasonographic data in psoriatic and PsA patients, as well as the role of dermatological and rheumatological assessment for the shared management of this heterogeneous condition, and pilot studies for new therapeutic approaches in PsA with an eye towards the future.

Dr. Alen Zabotti
Dr. Ivan Giovannini
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • psoriatic arthritis
  • psoriasis
  • ultrasonography
  • imaging
  • early diagnosis
  • biomarker
  • disease interception
  • screening tool
  • janus kinase inhibition
  • IL23

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

8 pages, 437 KiB  
Article
Differentiated Effect of Smoking on Disease Activity and Quality of Life among Different Spondyloarthritis Phenotypes
by Sara Alonso-Castro, Andrea García-Valle, Isla Morante-Bolado, Ignacio Braña, Estefanía Pardo and Rubén Queiro
J. Clin. Med. 2023, 12(2), 551; https://doi.org/10.3390/jcm12020551 - 10 Jan 2023
Cited by 2 | Viewed by 1339
Abstract
Background and aims: The effect of smoking on disease activity and quality of life (QoL) in spondyloarthritis (SpA) is far from clear. We aimed to evaluate the relationship between smoking and these outcomes in patients with axial SpA (axSpA) and psoriatic arthritis (PsA). [...] Read more.
Background and aims: The effect of smoking on disease activity and quality of life (QoL) in spondyloarthritis (SpA) is far from clear. We aimed to evaluate the relationship between smoking and these outcomes in patients with axial SpA (axSpA) and psoriatic arthritis (PsA). Patients and methods: This cross-sectional observational multicenter study included 242 patients with axSpA and 90 with PsA. The association between conventional cardiovascular risk factors and disease activity as well as QoL, in both SpA phenotypes was evaluated. For this, univariate and multivariate regression analyses were performed, as well as confirmatory meta-analyses. Results: Regardless of age, sex, or disease duration, patients with axSpA showed significantly less association with obesity (OR 0.50 (0.26–0.96), p = 0.03) and hypertension (OR 0.33 (0.18–0.62), p = 0.0005). However, axSpA was significantly associated with smoking (OR 2.62 (1.36–5.04), p = 0.004). Patients with axSpA were more likely to be in a category of high disease activity compared with PsA (OR 2.86, p = 0.0006). Regardless of sex, age, disease duration, and education level, smoking was significantly associated with higher disease activity in axSpA (OR 1.88, p = 0.027). A fixed-effects model meta-analysis (OR 1.70, p = 0.038) confirmed the association between tobacco and disease activity. No relationship was found between smoking (or other cardiometabolic risk factors) and structural damage or worse QoL in either disease. Conclusions: Although the cardiometabolic risk profile is clearly different between both SpA phenotypes, the only clear link between these factors and increased disease activity was observed between smoking and axSpA. Our findings need further confirmation. Full article
(This article belongs to the Special Issue Clinical Management of Psoriatic Arthritis: Future Perspectives)
►▼ Show Figures

Figure 1

8 pages, 1342 KiB  
Article
Treatment Retention and Safety of Ixekizumab in Psoriatic Arthritis: A Real Life Single-Center Experience
by Ignacio Braña, Estefanía Pardo, Stefanie Burger, Pablo González del Pozo, Mercedes Alperi and Rubén Queiro
J. Clin. Med. 2023, 12(2), 467; https://doi.org/10.3390/jcm12020467 - 6 Jan 2023
Cited by 4 | Viewed by 1912
Abstract
Background and objectives: Information on the performance of ixekizumab (IXE) in patients with psoriatic arthritis (PsA) in clinical practice is scarce. We aimed to analyze the retention rate and safety of IXE in patients with PsA in routine clinical practice. Methods: A retrospective [...] Read more.
Background and objectives: Information on the performance of ixekizumab (IXE) in patients with psoriatic arthritis (PsA) in clinical practice is scarce. We aimed to analyze the retention rate and safety of IXE in patients with PsA in routine clinical practice. Methods: A retrospective longitudinal observational single-center study of all patients with PsA who had received at least one dose of IXE. Adverse events (AEs) and drug retention rate were the main study focus. Survival was analyzed using Kaplan–Meier curves and predictive factors using multivariate Cox regression analysis. The hazard ratio (HR) was used as a measure of the association. Results: Seventy-two patients were included (52 women and 20 men). Median disease duration was 5 years (IQR 3–9). More than 90% received ≥2 biologic and/or targeted synthetic disease-modifying anti-rheumatic drugs (DMARDs) prior to IXE. Ixekizumab showed a 1-year retention rate of 65% and a 2-year retention rate of 57%. Regarding discontinuation due to AEs, 0.18 AEs per person-year were identified. The number of previous biologics did not influence drug survival but prior use of methotrexate (HR 2.31 (95% CI 1.05–5.10), p < 0.05) and depression (HR 2.40 (95% CI 1.07–5.41), p < 0.05) increased the risk of IXE discontinuation. Conclusions: Ixekizumab showed a good retention rate in a PsA population mostly refractory to biologic and targeted synthetic DMARDs. Drug survival was consistently good regardless of age, gender, metabolic comorbidities, smoking status, or prior number of biologic therapies. This information may be of interest to better position this drug in the PsA treatment algorithms. Full article
(This article belongs to the Special Issue Clinical Management of Psoriatic Arthritis: Future Perspectives)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop